ABSTRACT
Levodopa-induced dyskinesia (LID) is a common complication of Parkinson's disease (PD) therapy. Nitric oxide in the central nervous system may have a role in its pathophysiology. The present work investigates plasma and CSF levels of nitric oxide metabolites nitrite and nitrate in patients with PD, LID, and healthy control. We measured plasma and CSF nitrite and nitrate levels in patients with PD with and without LID and in healthy controls. The levels of plasma and CSF nitrite and nitrate were measured by ozone-based chemiluminescence. Sixty-seven participants were enrolled. CSF nitrite levels in patients with PD and LID were higher than in patients with PD without LID and healthy controls. CSF/plasma ratio of nitrite was higher in patients with PD and LID than in patients with PD without LID. The CSF/plasma ratio of nitrite in patients with PD and LID was higher than 1, indicating an intrathecal production of NO in patients with this motor complication. There was an increase in nitrate levels of CSF and CSF/plasma ratio of nitrate in patients with PD and LID compared to the healthy controls. Sex, age at evaluation, disease duration, and levodopa equivalent daily doses, as well as processing and storage time, did not critically influence these results. The present study demonstrated an increase in nitrite and nitrate levels in the central nervous system of patients with PD and LID. This finding strengthens the role of NO on LID pathophysiology.
Subject(s)
Dyskinesias , Parkinson Disease , Antiparkinson Agents/adverse effects , Humans , Levodopa/adverse effects , Nitric OxideABSTRACT
Nitric oxide (NO) triggers escape reactions in the dorsal periaqueductal gray matter (dPAG), a core structure mediating panic-associated response, and decreases the release of BDNF in vitro. BDNF mediates the panicolytic effect induced by antidepressant drugs and produces these effects per se when injected into the dPAG. Based on these findings, we hypothesize that nitric oxide synthase (NOS) inhibitors would have panicolytic properties associated with increased BDNF signaling in the dPAG. We observed that the repeated (7â¯days), but not acute (1â¯day), systemic administration of the NOS inhibitor aminoguanidine (AMG; 15â¯mg/kg/day) increased the latency to escape from the open arm of the elevated T-maze (ETM) and inhibited the number of jumps in hypoxia-induced escape reaction in rats, suggesting a panicolytic-like effect. Repeated, but not acute, AMG administration (15â¯mg/kg) also decreased nitrite levels and increased TRKB phosphorylation at residues Y706/7 in the dPAG. Notwithstanding the lack of AMG effect on total BDNF levels in this structure, the microinjection of the TRK antagonist K252a into the dPAG blocked the anti-escape effect of this drug in the ETM. Taken together our data suggest that the inhibition of NO production by AMG increases the levels of pTRKB, which is required for the panicolytic-like effect observed.
Subject(s)
Anti-Anxiety Agents/pharmacology , Guanidines/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Panic/drug effects , Receptor, trkB/drug effects , Animals , Blotting, Western , Brain-Derived Neurotrophic Factor/metabolism , Escape Reaction/drug effects , Male , Maze Learning/drug effects , Motor Activity/drug effects , Nitrites/metabolism , Periaqueductal Gray/drug effects , Periaqueductal Gray/metabolism , Periaqueductal Gray/physiology , Phosphorylation/drug effects , Rats , Rats, Wistar , Receptor, trkB/antagonists & inhibitors , Receptor, trkB/metabolism , Signal Transduction/drug effectsABSTRACT
A produção magistral do xarope de guaco, obtido a partir do extrato fluido do guaco (Mikania glomerata Spreng., Asteraceae) e comercializada na Farmácia Universitária da UFJF/MG, gerou um projeto de pesquisa com o objetivo principal de estudar a estabilidade do produto acabado, tendo como ponto de referência a determinação do teor de cumarina das amostras armazenadas em diferentes temperaturas. O método aplicado para realizar a análise do teor de cumarina presente no xarope em estudo foi espectrometria no UV com comprimento de onda de 275,4 nm. Utilizou-se como veículo para efetuar as diluições da amostra uma mistura de metanol/água destilada, na proporção de 80 por cento v/v. A curva de calibração foi obtida diluindo-se 100 mg de cumarina padrão em 100 mL da solução descrito acima, obtendo-se sete concentrações distintas com variação de 2 µg a 20 µg. Os resultados obtidos demonstraram que a temperatura de armazenamento de 45 °C foi considerada ótima para desenvolver a conversão do isômero trans em cis com subseqüente conversão deste a cumarina. Os valores de cumarina encontrados na forma farmacêutica em estudo foram de 1,19 a 1,37 mg/mL, sendo que o valor mais alto refere-se às amostras armazenadas a 45°C durante seis meses.
The production of guaco syrup, obtained from guaco (Mikania glomerata Spreng., Asteraceae) fluid extract, and commercialized by the University Pharmacy of the Federal University of Juiz de Fora-MG, Brazil, led to a research project whose main aim was to study the stability of the finished product, with reference to the coumarin content of samples stored at different temperatures. UV spectrophotometry (275.4 nm) was used to assess the coumarin content of the study syrup. An 80 percent v/v methanol/distilled water mixture was used for sample dilution. The calibration curve was constructed by the dilution of 100 mg standard coumarin in 100 ml of the aforementioned solution, with seven distinct concentrations (ranging from 2 µg a 20 µg) being obtained. The results showed the 45 °C storage temperature to be optimum for the development of trans-cis isomerization, with subsequent conversion of the latter into coumarin. Coumarin content in the studied pharmaceutical presentation ranged from 1.19 to 1.37 mg/mL, the highest value corresponding to the samples stored at 45 °C for six months.
